CoChat

Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia

Open access

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Among Asian countries, South Korea was the first to approve liraglutide as a treatment for obesity. Thus, the clinical effectiveness of liraglutide has not been studied in Asian populations. In this study, we retrospectively analyzed obese patients [body mass index (BMI) >27 kg/m 2] who were treated with liraglutide between March 2018 and March 2019 in a single clinic. Weight, BMI, HbA1c, and clinical data were collected before liraglutide treatment. Changes in body weight and composition and their relationships with clinical variables were examined at re-prescription dates within 30, 60, 90, and 180 days. A total of 169 subjects were studied. The average age was 41.5 years, and 42% of the subjects were male. The average weight was 85.2 kg, and the average BMI was 30.8 kg/m 2. Weight reduction was significant (–5.5 ± 3.4 kg, 30 days: –3.2 ± 1.8 kg, 60 days: –4.5 ± 2.3 kg, 90 days: –6.3 ± 2.6 kg, 180 days: –7.8 ± 3.5 kg) during the follow-up period and increased with longer treatment time (P < .001). The percentages of subjects that showed ≥ 5% and ≥ 10% body weight reduction were 62.1% and 17.2%, respectively. In the body composition analysis, skeletal muscle weight loss was –3.56 ± 29.7%, which was significantly smaller than fat weight loss of –11.06 ± 10.4% (P = .03). Weight loss was not significantly related to age, sex, baseline BMI, baseline HbA1c, smoking status, alcohol consumption, coffee intake. In conclusion, Liraglutide treatment led to meaningful weight loss in South Korean patients, and fat mass reduction was prominent during treatment. Furthermore, liraglutide showed greater clinical effectiveness with longer treatment time.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000023780

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (A) Flow chart of the study. (B) Dose escalation schedule of liraglutide treatment.
Figure 1 (A) Flow chart of the study. (B) Dose escalation schedule of liraglutide treatment.CC BY-NC · PubMed Central
Figure 2 (A) Weight loss (%) according to the duration of liraglutide treatment. Longer use of liraglutide significantly reduced body weight. Linear regression analysis was performed. (B) Change in muscle weight and fat weight by kg (B) and percentage (C). During liraglutide treatment, fat mass was significantly more reduced compared with muscle mass. Error bars represent ± SD. Student t-tests were performed.
Figure 2 (A) Weight loss (%) according to the duration of liraglutide treatment. Longer use of liraglutide significantly reduced body weight. Linear regression analysis was performed. (B) Change in muscle weight and fat weight by kg (B) and percentage (C). During liraglutide treatment, fat mass was significantly more reduced compared with muscle mass. Error bars represent ± SD. Student t-tests were performed.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 31

Metadata

Authors
Park, J. S., Kwon, J., Choi, H. J., & Lee, C.
Affiliations
  • Seoul National University (KR)
  • Seoul Happiness Clinic of Internal Medicine, Republic of Korea.
Corresponding author
Lee, Changhyun
Venue
Medicine
Published
2021-01-15
Volume
100
Issue
2
Pages
e23780
ISSN
  • 0025-7974 (ISSN-L)
  • 1536-5964
OpenAlex
W3120644852
Cited by
27
References
27
Citations by year
2026: 2 · 2025: 5 · 2024: 7 · 2023: 9 · 2022: 4
FWCI
2.92
Type
journal article
Language
en
Open access
Locations
  • Medicine (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
  • National Research Foundation of Korea (NRF) Grant funded by the Korean Government [MIST] (NRF-2018R1A5A2025964)
  • Creative-Pioneering Researchers Program through Seoul National University (SNU) The Seoul National University Hospital Medical Research Collaborating Center (none)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
liraglutide, obesity, weight loss, GLP-1 receptor agonists, body composition, fat mass reduction, skeletal muscle, South Korean patients, Asian populations, treatment duration
MeSH terms
Liraglutide, Adult, Blood Glucose, Body Weights and Measures, Dose-Response Relationship, Drug, Female, Glycated Hemoglobin, Humans, Life Style, Male, Middle Aged, Obesity, Retrospective Studies, Weight Loss, Body Mass Index, Glucagon-Like Peptide 1, Republic of Korea

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia. https://app.cochat.ai/papers/10.1097/md.0000000000023780
The paper
Park, J. S., Kwon, J., Choi, H. J., & Lee, C. (2021). Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia. Medicine. https://doi.org/10.1097/md.0000000000023780

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.